Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/THBS1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/THBS1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/THBS1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/THBS1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/THBS1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007156024 | Oral cavity | NEOLP | cellular response to transforming growth factor beta stimulus | 58/2005 | 250/18723 | 9.13e-09 | 4.56e-07 | 58 |
GO:200011632 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity | 55/2005 | 235/18723 | 1.59e-08 | 7.25e-07 | 55 |
GO:200011732 | Oral cavity | NEOLP | negative regulation of cysteine-type endopeptidase activity | 28/2005 | 86/18723 | 3.84e-08 | 1.60e-06 | 28 |
GO:000717923 | Oral cavity | NEOLP | transforming growth factor beta receptor signaling pathway | 48/2005 | 198/18723 | 4.01e-08 | 1.66e-06 | 48 |
GO:004315432 | Oral cavity | NEOLP | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 26/2005 | 78/18723 | 6.80e-08 | 2.61e-06 | 26 |
GO:004328132 | Oral cavity | NEOLP | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 49/2005 | 209/18723 | 8.94e-08 | 3.36e-06 | 49 |
GO:005134631 | Oral cavity | NEOLP | negative regulation of hydrolase activity | 75/2005 | 379/18723 | 9.98e-08 | 3.66e-06 | 75 |
GO:003300221 | Oral cavity | NEOLP | muscle cell proliferation | 55/2005 | 248/18723 | 1.11e-07 | 4.03e-06 | 55 |
GO:001046632 | Oral cavity | NEOLP | negative regulation of peptidase activity | 57/2005 | 262/18723 | 1.32e-07 | 4.65e-06 | 57 |
GO:003497632 | Oral cavity | NEOLP | response to endoplasmic reticulum stress | 56/2005 | 256/18723 | 1.39e-07 | 4.84e-06 | 56 |
GO:001095132 | Oral cavity | NEOLP | negative regulation of endopeptidase activity | 55/2005 | 252/18723 | 1.94e-07 | 6.52e-06 | 55 |
GO:003210323 | Oral cavity | NEOLP | positive regulation of response to external stimulus | 81/2005 | 427/18723 | 2.04e-07 | 6.74e-06 | 81 |
GO:003461231 | Oral cavity | NEOLP | response to tumor necrosis factor | 55/2005 | 253/18723 | 2.23e-07 | 7.28e-06 | 55 |
GO:200123532 | Oral cavity | NEOLP | positive regulation of apoptotic signaling pathway | 34/2005 | 126/18723 | 2.55e-07 | 8.23e-06 | 34 |
GO:007048232 | Oral cavity | NEOLP | response to oxygen levels | 69/2005 | 347/18723 | 2.66e-07 | 8.54e-06 | 69 |
GO:000166632 | Oral cavity | NEOLP | response to hypoxia | 63/2005 | 307/18723 | 2.75e-07 | 8.78e-06 | 63 |
GO:190188814 | Oral cavity | NEOLP | regulation of cell junction assembly | 47/2005 | 204/18723 | 2.82e-07 | 8.96e-06 | 47 |
GO:000717822 | Oral cavity | NEOLP | transmembrane receptor protein serine/threonine kinase signaling pathway | 70/2005 | 355/18723 | 3.04e-07 | 9.62e-06 | 70 |
GO:003629332 | Oral cavity | NEOLP | response to decreased oxygen levels | 65/2005 | 322/18723 | 3.34e-07 | 1.04e-05 | 65 |
GO:004572732 | Oral cavity | NEOLP | positive regulation of translation | 35/2005 | 136/18723 | 5.91e-07 | 1.74e-05 | 35 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
THBS1 | SNV | Missense_Mutation | | c.3229C>T | p.Arg1077Trp | p.R1077W | P07996 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.2476N>G | p.Met826Val | p.M826V | P07996 | protein_coding | tolerated(0.44) | benign(0.015) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | | c.1472N>A | p.Ile491Asn | p.I491N | P07996 | protein_coding | deleterious(0) | possibly_damaging(0.907) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
THBS1 | SNV | Missense_Mutation | rs576321057 | c.2318G>A | p.Arg773His | p.R773H | P07996 | protein_coding | deleterious(0.05) | possibly_damaging(0.591) | TCGA-E2-A14P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Targeted Molecular therapy | trastuzumab | SD |
THBS1 | SNV | Missense_Mutation | novel | c.905N>T | p.Thr302Ile | p.T302I | P07996 | protein_coding | tolerated(0.05) | benign(0.216) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1869_1870insA | p.Phe624IlefsTer25 | p.F624Ifs*25 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.1871_1872insTGTGACCATCAACTCTGTA | p.Thr625ValfsTer30 | p.T625Vfs*30 | P07996 | protein_coding | | | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.236_237insCTTAA | p.Asp80LeufsTer17 | p.D80Lfs*17 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Nonsense_Mutation | novel | c.237_238insAGTTGAGAGATTTAGCAGCTCAAAAATGTGACCT | p.Asp80SerfsTer2 | p.D80Sfs*2 | P07996 | protein_coding | | | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
THBS1 | insertion | Frame_Shift_Ins | novel | c.988_989insTTCCAGCCCTGCCATCCGCACTAACTACATTGGCCACAAGACA | p.Glu330ValfsTer19 | p.E330Vfs*19 | P07996 | protein_coding | | | TCGA-AN-A049-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2&APOS;-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | METHYLCELLULOSE | METHYLCELLULOSE | 9016860 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | PROTEIN KINASE C INHIBITOR | | 9223624 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | SIMVASTATIN | SIMVASTATIN | 10543307 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | UVB | | 14962109 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | 5-AZA-2-DEOXYCYTIDINE | | 14559817 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ABT-510 | ABT-510 | |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | VESNARINONE | VESNARINONE | 15356428 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | ALL-TRANS RETINOIC ACID | | 9447832 |
7057 | THBS1 | EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | | RETINOIC ACID | | 1430209 |